Meeting
2021 Genitourinary Cancers Symposium
Impact of treatment and frailty on elder-relevant physical function outcomes in older adults with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Helen Yang
University of Toronto, Toronto, ON, Canada
Helen Yang , Henriette Breunis , Narhari Timilshina , Seungyeon Kim , Shabbir M.H. Alibhai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Advanced Disease
Track
Prostate Cancer - Advanced
Sub Track
Symptoms, Toxicities, and Whole-Person Care
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 76)
DOI
10.1200/JCO.2021.39.6_suppl.76
Abstract #
76
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
The potential role of frailty in modifying quality-of-life related outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients receiving docetaxel, abiraterone, enzalutamine, and radium 223.
First Author: Seungyeon Kim
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world treatment (Tx) sequences and time to discontinuation (rwTTD) in the first-line (1L) metastatic castration-resistant prostate cancer (mCRPC) setting.
First Author: Emily Nash Smyth
Poster
2024 ASCO Genitourinary Cancers Symposium
LORIKEET: A phase 2, randomized, open-label study of lorigerlimab plus docetaxel versus docetaxel alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Sumit Kumar Subudhi
Poster
2024 ASCO Genitourinary Cancers Symposium
First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Dana E. Rathkopf